Patents Assigned to Pharming
-
Patent number: 7442392Abstract: The invention provides the use of loquat kernel to kill, inactivate or repel pests, in particular nematodes. Also provided is a method of killing, inactivating or repelling nematodes, which method comprises providing loquat kernel and applying the loquat kernel to the nematodes or to an area where the nematodes are likely to exist or to an area to where the nematodes are expected to move. The invention further provides a pesticide comprising loquat kernel and a pesticidally acceptable solvent, carrier, excipient or diluent; and a method of producing a pesticide, which method comprises providing ground, chopped, freeze dried or spray dried loquat kernel.Type: GrantFiled: February 7, 2005Date of Patent: October 28, 2008Assignee: Pharming Ltd.Inventors: Ivo Baekelmans, Ron Herbert Brown, Irene Mueller-Harvey
-
Publication number: 20070248699Abstract: The invention provides the use of loquat kernel to kill, inactivate or repel pests, in particular nematodes. Also provided is a method of killing, inactivating or repelling nematodes, which method comprises providing loquat kernel and applying the loquat kernel to the nematodes or to an area where the nematodes are likely to exist or to an area to where the nematodes are expected to move. The invention further provides a pesticide comprising loquat kernel and a pesticidally acceptable solvent, carrier, excipient or diluent; and a method of producing a pesticide, which method comprises providing ground, chopped, freeze dried or spray dried loquat kernel.Type: ApplicationFiled: February 7, 2005Publication date: October 25, 2007Applicant: PHARMING LTD.Inventors: Ivo Baekelmans, Ron Brown, Irene Mueller-Harvey
-
Publication number: 20070219352Abstract: The present invention provides a method for the part purification of fibrinogen from milk, the method comprising the transfer of protease enzyme which is present in the milk, into the whey phase with the removal or partition of fibrinogen into another phase of the milk. The present invention also provides a method for obtaining fibrinogen from a fluid, the method comprising: a) contacting the fluid with a hydrophobic interaction chromatography resin under conditions where the fibrinogen binds to the resin; and b) removing the bound protein by means of elution.Type: ApplicationFiled: April 9, 2007Publication date: September 20, 2007Applicant: Pharming Intellectual Property BVInventors: Graham McCreath, Michael Udell
-
Publication number: 20070185011Abstract: The present invention relates to the use of a C1 inhibitor (C1INH) with shorter half-life than plasma-derived C1INH for the preparation of a medicament for the transient treatment of an individual. It relates to both therapeutic and prophylactic treatment. The method of the invention allows for the administration of C1INH at certain therapeutic levels for a concise pre-determined time span. Pharmaceutical compositions based on C1INH with shorter half-lives may be used both in situations where transient treatment is merely and advantage. The advantage of the use according to the invention is that an individual is not exposed to C1INH for longer than required, since the levels of the C1INH more rapidly subsides after administration has stopped. In contrast, levels of plasma-derived C1INH would remain elevated for a prolonged period of time.Type: ApplicationFiled: May 14, 2004Publication date: August 9, 2007Applicant: Pharming Intellectual Property B.V.Inventor: Johannes Nuijens
-
Patent number: 7211650Abstract: The present invention provides a method for the part purification of fibrinogen from milk, the method comprising the transfer of protease enzyme which is present in the milk, into the whey phase with the removal or partition if fibrinogen into another phase of the milk. The present invention also provides a method for obtaining fibrinogen from a fluid, the method comprising: a) contacting the fluid with a hydrophobic interaction chromatography resin under conditions where the fibrinogen binds to the resin; and b) removing the bound protein by means of elution.Type: GrantFiled: March 22, 2001Date of Patent: May 1, 2007Assignee: Pharming Intellectual Property BVInventors: Graham McCreath, Udell Michael
-
Patent number: 7067713Abstract: The invention provides transgenic nonhuman mammals expressing C1 inhibitor in their milk. The C1 inhibitor is useful in treating patients with hereditary angioedema or patients requiring immunosuppression.Type: GrantFiled: January 31, 2001Date of Patent: June 27, 2006Assignee: Pharming Intellectual Property B.V.Inventors: Jan Henricus Nuijens, Henricus Antonius Van Veen, Frank Robert Pieper, Joris Jan Heus
-
Patent number: 7045677Abstract: A process for the production of a peptide is disclosed, the process comprising expressing in the milk of a transgenic, non-human, placental mammal a fusion protein which comprises the peptide to be expressed linked to a fusion partner protein which is lysozyme. The fusion protein may be separate from the milk and cleaved to yield the target peptide. A transgenic, non-human, placental mammal whose genome incorporates a DNA molecule comprising a coding sequence encoding lysozyme coupled to a peptide is also described.Type: GrantFiled: December 21, 2001Date of Patent: May 16, 2006Assignee: Pharming Intellectual Property BVInventors: Ian Robert Cottingham, Graham Edward McCreath
-
Publication number: 20050223416Abstract: The invention provides transgenic nonhuman mammals expressing C1 inhibitor in their milk. The C1 inhibitor is useful in treating patients with hereditary angioedema or patients requiring immunosuppression.Type: ApplicationFiled: March 22, 2005Publication date: October 6, 2005Applicant: Pharming Intellectual Property B.V.Inventors: Johannes Nuijens, Henricus Van Veen, Frank Pieper, Joris Heus
-
Publication number: 20050198698Abstract: Transgenes for producing recombinant polypeptides transgenic bovine species. A transgene for producing recombinant polypeptides in the milk of transgenic bovine species comprises at least one expression regulation sequence, a secretory DNA sequence encoding a secretory signal sequence which is functional in mammary secretory cells of the bovine species and a recombinant DNA sequence encoding the recombinant polypeptide. Also included are methods for producing transgenic bovine species. The method includes introducing the above transgene into an embryonal target cell of a bovine species, transplanting the transgenic embryonic target cell formed thereby into a recipient bovine parent and identifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk.Type: ApplicationFiled: November 12, 2004Publication date: September 8, 2005Applicant: Pharming B.V., a Netherlands corporationInventors: Herman DeBoer, Rein Strijker, Herbert Heyneker, Gerard Plantenburg, Sang Lee, Frank Pieper, Paul Krimpenfort
-
Publication number: 20050172342Abstract: The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorporation into the mammals are also provided.Type: ApplicationFiled: December 18, 2003Publication date: August 4, 2005Applicants: Pharming B.V., Cohesion Technologies, Inc.Inventors: Costas Karatzas, Frank Pieper, Ineke De Wit, Richard Berg, Gerard Platenburg, Paul Toman
-
Publication number: 20040266711Abstract: Described is a method of targeting specific genes to the mammary gland which results in the efficient synthesis and secretion of biologically important molecules. Further, there is described as a composition of matter, a transgenic mammal having the ability to reproduce itself and being suitable for the secretion of biologically active agents into its milk. Additionally there is disclosed as a composition of matter, recombinant DNA gene complexes designed to integrate into a mammalian genome and to synthesize and secrete biological active agents into the milk. Furthermore, methods of producing and using altered milk are disclosed.Type: ApplicationFiled: March 3, 2004Publication date: December 30, 2004Applicant: Pharming B.V.Inventor: Jeffrey M. Rosen
-
Publication number: 20040250300Abstract: This invention relates to the production of recombinant proteins in mammals' milk. Particularly, this invention relates to an expression system which when transgenically incorporated into a mammal permits the female species of that mammal to produce the desired recombinant protein in or along with its milk. This invention also relates to the transgenic mammal that produces the desired recombinant product in its milk.Type: ApplicationFiled: March 2, 2004Publication date: December 9, 2004Applicant: Pharming B.V.Inventors: Harry Meade, Nils Lonberg
-
Publication number: 20040081645Abstract: The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient.Type: ApplicationFiled: June 30, 2003Publication date: April 29, 2004Applicants: Genzyme Corporation, Pharming Intellectual Property B.V.Inventors: Johannes B.M.M. Van Bree, Edna H.G. Venneker, David P. Meeker
-
Patent number: 6713662Abstract: The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorporation into the mammals are also provided.Type: GrantFiled: June 7, 1995Date of Patent: March 30, 2004Assignees: Pharming Intellectual Property B.V., Cohesion TechnologiesInventors: Costas N. Karatzas, Frank Pieper, Ineke De Wit, Richard Berg, Gerard Platenburg, Paul David Toman
-
Publication number: 20040003421Abstract: The invention provides transgenic nonhuman mammals producing phosphorylated lysosomal proteins in their milk, and methods of generating the same. Phosphorylation occurs at the 6′ position of a mannose side chain residue. Also provided are methods of purifying lysosomal proteins from milk, and incorporating the proteins into pharmaceutical compositions for use in enzyme replacement therapy.Type: ApplicationFiled: January 23, 2003Publication date: January 1, 2004Applicant: Pharming B.V.Inventors: Arnold J.J. Reuser, Ans T. Van der Ploeg, Frank R. Pieper, Martin Ph. Verbeet
-
Publication number: 20030192068Abstract: Transgenes for producing recombinant polypeptides transgenic bovine species. A transgene for producing recombinant polypeptides in the milk of transgenic bovine species comprises at least one expression regulation sequence, a secretory DNA sequence encoding a secretory signal sequence which is functional in mammary secretory cells of the bovine species and a recombinant DNA sequence encoding the recombinant polypeptide. Also included are methods for producing transgenic bovine species. The method includes introducing the above transgene into an embryonal target cell of a bovine species, transplanting the transgenic embryonic target cell formed thereby into a recipient bovine parent and identifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk.Type: ApplicationFiled: June 11, 2002Publication date: October 9, 2003Applicant: Pharming B.V.Inventors: Herman A. DeBoer, Rein Strijker, Herbert L. Heynecker, Gerard Platenburg, Sang Ha Lee, Frank Pieper, Paul J.A. Krimpenfort
-
Patent number: 6495344Abstract: A DNA molecule coding for a food protein, such as ovalbumin or casein, modified so that the codons for phenylalanine have been omitted or replaced by codons for one or more other metabolisable amino acids. Also a modified edible protein coded for by such a DNA molecule. Such modified proteins are useful in the nutrition of patients suffering from phenylketonuria.Type: GrantFiled: January 16, 1996Date of Patent: December 17, 2002Assignee: Pharming Holding N. V.Inventors: Noel Gordon Carr, Nicholas Harold Mann
-
Patent number: 6333311Abstract: The invention provides compositions containing human lactoferrin, or lactoferrin variants deleted for one or more arginine residues in the amino-terminal region of the protein (i.e., in the first basic cluster), and methods of using the compositions. The human lactoferrin, or lactoferrin variants are useful for treatment of human diseases and conditions, including inflamation.Type: GrantFiled: February 2, 1998Date of Patent: December 25, 2001Assignee: PharmingInventors: Jan Nuijens, Patrick van Berkel
-
Patent number: 6140552Abstract: Transgenes for producing recombinant polypeptides transgenic bovine species. A transgene for producing recombinant polypeptides in the milk of transgenic bovine species comprises at least one expression regulation sequence, a secretory DNA sequence encoding a secretory signal sequence which is functional in mammary secretory cells of the bovine species and a recombinant DNA sequence encoding the recombinant polypeptide. Also included are methods for producing transgenic bovine species. The method includes introducing the above transgene into an embryonal target cell of a bovine species, transplanting the transgenic embryonic target cell formed thereby into a recipient bovine parent and identifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk.Type: GrantFiled: June 7, 1995Date of Patent: October 31, 2000Assignee: Pharming B.V.Inventors: Herman A. Deboer, Rein Strijker, Herbert L. Heyneker, Gerard Platenburg, Sang He Lee, Frank Pieper, Paul J. A. Krimpenfort
-
Patent number: 6118045Abstract: The invention provides transgenic nonhuman mammals producing phosphorylated lysosomal proteins in their milk, and methods of generating the same. Phosphorylation occurs at the 6' position of a mannose side chain residue. Also provided are methods of purifying lysosomal proteins from milk, and incorporating the proteins into pharmaceutical compositions for use in enzyme replacement therapy.Type: GrantFiled: July 29, 1996Date of Patent: September 12, 2000Assignees: Pharming B.V., The Universiteit Leiden, Academic Hospital, Eramus UniversiteitInventors: Arnold J. J. Reuser, Ans T. Van der Ploeg, Frank R. Pieper, Martin Ph. Verbeet